Lowers the risk of cardiovascular mortality and heart failure hospitalizations. ANDA 211143, held by Alkem Labs Ltd. Metoprolol Succinate.
As of Nov 16, 2026, ANDA 211143 (Metoprolol Succinate), held by Alkem Labs Ltd, was first approved by FDA on Nov 25, 2020, with 3 approved supplements and 0 published complete response letters.
Metoprolol succinate, is a beta-adrenergic blocker indicated for the treatment of:
| Date | Submission | Status | Documents |
|---|---|---|---|
| Nov 25, 2020 | Original application | Approved | None posted |
| Metoprolol SuccinateEQ 25MG TARTRATE · tablet, extended release;oral | Metoprolol Succinate | Rx |
| Metoprolol SuccinateEQ 50MG TARTRATE · tablet, extended release;oral | Metoprolol Succinate | Rx |
| Metoprolol SuccinateEQ 100MG TARTRATE · tablet, extended release;oral | Metoprolol Succinate | Rx |
| Metoprolol SuccinateEQ 200MG TARTRATE · tablet, extended release;oral | Metoprolol Succinate | Rx |
| Jul 3, 2023 | Supplement 4Labeling · Standard review | Approved | None posted |
| Nov 8, 2022 | Supplement 3Labeling · Standard review | Approved | None posted |
| Aug 16, 2022 | Supplement 2Labeling · Standard review | Approved | None posted |
| Nov 25, 2020 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters